Literature DB >> 2120130

Regulation by interleukin-3 of human monocyte pro-inflammatory mediators. Similarities with granulocyte-macrophage colony-stimulating factor.

P H Hart1, G A Whitty, D R Burgess, J A Hamilton.   

Abstract

Urokinase-type plasminogen activator (u-PA), tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) activities were measured for highly purified human monocytes cultured for 18 hr with recombinant human interleukin-3 (IL-3). IL-3 alone stimulated monocyte u-PA activity, but not TNF-alpha or IL-1 activity. However, IL-3, together with interferon-gamma (IFN-gamma), stimulated the TNF-alpha, but not IL-1, activities of monocytes from several donors. In parallel cultures, granulocyte-macrophage colony-stimulating factor (GM-CSF) behaved similarly. IL-3, like GM-CSF, synergized weakly and sometimes irregularly with lipopolysaccharide (LPS) for increased TNF-alpha and IL-1 activities. Thus, IL-3 can selectively stimulate monocyte mediator production depending on the costimulus present; however, the stimulatory properties of IL-3 vary from those of IFN-gamma and IL-4. The similarities in activity between IL-3 and GM-CSF may be explained by a common or associated IL-3/GM-CSF receptor(s), as suggested by biochemical studies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120130      PMCID: PMC1384224     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Hematopoietic growth factors.

Authors:  C A Sieff
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

Review 2.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

3.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

4.  Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism.

Authors:  S A Cannistra; E Vellenga; P Groshek; A Rambaldi; J D Griffin
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

5.  Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator.

Authors:  Z Werb; C L Mainardi; C A Vater; E D Harris
Journal:  N Engl J Med       Date:  1977-05-05       Impact factor: 91.245

6.  Induction of macrophage plasminogen activator by endotoxin stimulation and phagocytosis: evidence for a two-stage process.

Authors:  S Gordon; J C Unkeless; Z A Cohn
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

7.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

8.  Specific binding of radioiodinated granulocyte-macrophage colony-stimulating factor to hemopoietic cells.

Authors:  F Walker; A W Burgess
Journal:  EMBO J       Date:  1985-04       Impact factor: 11.598

9.  Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3.

Authors:  A F Lopez; L B To; Y C Yang; J R Gamble; M F Shannon; G F Burns; P G Dyson; C A Juttner; S Clark; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

10.  Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.

Authors:  A Wohlwend; D Belin; J D Vassalli
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases.

Authors:  John A Hamilton; Andrew D Cook; Paul P Tak
Journal:  Nat Rev Drug Discov       Date:  2016-12-29       Impact factor: 84.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.